Whats Next for Value Based Care? 4.26.19 Introductions Dave - - PowerPoint PPT Presentation
Whats Next for Value Based Care? 4.26.19 Introductions Dave - - PowerPoint PPT Presentation
Whats Next for Value Based Care? 4.26.19 Introductions Dave Spalding Erica Maltby 2017 co- Founded TMA 2017 co- Founded TMA Specialty Specialty Services Services CEO TMA Specialty Services VP Operations TMA Specialty
Dave Spalding
- 2017 co- Founded TMA
Specialty Services
- CEO TMA Specialty Services
- Has co-founded 3 value based
care companies, including TMA PracticeEdge
- HCSC/Blue Cross Executive
Introductions
Erica Maltby
- 2017 co- Founded TMA Specialty
Services
- VP Operations TMA Specialty
Services
- Consultant developing payer data
strategies around Value Based Care
- Innovation team at Optum
developing analytic products
- 1. Current state of Value
Based Care
- 2. Emerging Models
- 3. How to Prepare
Agenda
A Brief History of Value Based Care
- Value Based Care is the shift from payment based on Volume to Value
- Driven by MACRA legislation in 2015, which introduced MIPs and APMs to
Medicare payments
- MIPs and APMs seek to measure Value and incentivize lowering cost and
improving quality
- Objective of this shift is to align incentives of the entire healthcare system-
payers, providers, device makers, drug manufacturers, etc.
“Never, ever, think about something else when you should be thinking about the power of incentives”
- Charlie Munger
The Bad
- 1/5 dollars are spent on healthcare-
patients should expect Value
- Increased use of data and comfort
with reporting
- Bonus opportunity for APM
participation
The Good
- Investment required to stay
compliant is forcing out independent physicians
- Measures of value lack clinical
value
25% 25% 50% 50% 75% 75% 20% 20% 35% 35% 50% 50% 0% 20% 40% 60% 80% 2017 2018 2019 2020 2021 2022
Required Payments of Patients Thresholds per Program Year
Payments through APMs Patients in APMs
Value Based Spectrum
How is VBC defined?
Fee for Service Performance Bonus (P4P) Shared Savings Shared Risk Pay for Volume Bonuses for hitting Quality targets
- Defined measures in commercial contracts
- Device and drug manufacturers included
- “The agreement ties a component of our reimbursement to
successfully meeting clinical improvement thresholds”
- Medtronic and Aetna
Upside-only cost arrangements for beating benchmarks
- ACOs
- PCMHs
- ESCO
Upside / downside cost arrangements for beating benchmarks
- BPCIA
- ACO tracks 1+ - 3
- Capitation
APM Adoption Trends
TRENDS 2015-17
- Since 2015, the FFS-only (category 1) has
decreased from 63% of payments to 41%
- Shared savings and risk-based payments
(categories 3 & 4) have increased from 23% to 34% since 2015
- In 2017, Medicare Advantage led APM
adoption with 49.5% of payments in savings / risk models, including 15% in specialty episodes. Category 1 Category 2 Category 3 & 4 20 40 60 80 100 2015 2016 2017
HCP&LAN Payment Categories 2015-2017
Health Care Payment & Learning Action Network Annual Survey
- Data submitted by CMS, BCBSA, AHIP
- Over 82-84% of covered lives nationally
Category 1 – FFS Category 2 – Quality / P4P Category 3 – APM with FFS architecture Category 4 – Population-based risk
The commercial market lagged Medicare with 28% of payments in category 3 & 4 in 2017. Specialty episodes represented less than 8.5% of commercial VBC payments. 2019-20 Cost shifting benefits from high deductible plans are tapped out and employers are accelerating private sector adoption of APMs going in 2019-20. Large employers and purchasing coalitions are contracting directly with providers for specialty episodes and total cost of care deals.
ACO Model
- 10+ million Medicare
beneficiaries in ACO models
- Success in physician- led
ACOs
- Moving ACOs out of track 1
in 2019
- Can this model be used
more broadly in healthcare?
- $200
- $150
- $100
- $50
$0 $50 $100 $150 $200 $250 MD-owned Hospital
Savings vs. Benchmark Additional Savings ACO Payments Net Benefit/Loss to Medicare
2016 MSSP Results
- Primary care spend estimated at
10% of total healthcare spend
- High pricing is the driver behind
high costs- and specialists are in the driver’s seat
- CMS establishing Value- based
programs for specialists
- These programs focus on
team- care & cost containment of an area within specialists’ control
- BPCIA
- ESCOs
What about specialists?
CMS: Chronic Conditions Among Beneficiaries
Emerging Opportunities for Specialists
MEDICARE BPCIA
- 29 inpatient / 3 outpatient procedure
bundles
- Savings opportunity focused on post-
acute care re-design and efficiency
- Qualified APM at 20% upside /
downside risk
End Stage Renal “ESCO”
- ESRD ‘ACO’
- $51,000,000+ in shared savings
Oncology OCM
- Commercial payers invited to
participate
COMMERCIAL Currently limited to procedures such as colonoscopy and ortho. Most programs lack scalability and very few organizations are tackling chronic conditions Spotlight on Texas
- 1,500 BPCIA bundles approved
- Participants
- All major hospitals (UT led with 150+
bundles)
- Most regional medical centers
- Independent groups at less than 5%
- Convening organizations include:
Fusion5, Encompass, Remedy Partners and UnitedHealthcare
Challenges with Current Models
MEDICARE
- 90 days ‘all in’
- Focused on procedures
- Site of service opportunities neutralized
- Participation requires a convener
- Access to capital for risk
COMMERCIAL
- Very limited opportunities, focused on procedures
- Challenges with data sharing
- Upside only
- Undecided on which program to adopt
Our Proposal
- Follows the principal of shifting
payment from volume to value
- Synergy with existing ACO models
- For specialists, VBC will carve out
episodes- both procedures and chronic conditions- to manage
- Continue to align incentives
across the care continuum
Specialist Contract Methodologies
PROCEDURE EPISODES CONDITION EPISODES
Objectives
- Surgical quality & efficiency
- Managing pre/post procedure outcomes
- Identifying efficient provider partners
- Lowering procedure cost
Examples Colonoscopy, Joint Replacement, Coronary Bypass Cost Levers ▪ Unplanned event mitigation ▪ Site-of-service ▪ In-patient utilization ▪ In-network specialists ▪ Tools and techniques Immediate Opportunity Opportunities abound to lower costs by shifting site
- f service, reevaluating ancillary provider partners,
and changing clinical workflow patterns. Objectives
- Clinical quality & efficiency
- Early intervention and disease
management
- Coordination / Transitions of Care
- Patient experience
- Patient Education
Examples Heart Failure, Diabetes, COPD, CKD Cost Levers ▪ Care coordination with PCPs ▪ Patient compliance ▪ ER utilization ▪ Standards of care Immediate Opportunity Given the right data, specialists will be able to squeeze out unnecessary utilization of the healthcare system.
Case Study: Colonoscopy
Benchmark established by market average
Case Study: Colonoscopy
1
Identify cost buckets within a procedure
Case Study: Colonoscopy
2
Break down bucket 1: average pathology costs
Case Study: Colonoscopy
3
Break down bucket 2: average anesthesia costs
$1,900 $323
Case Study: Colonoscopy
4
Break down bucket 3: average facility fees
Case Study: Colonoscopy
5
Understand each individual physician’s provider mix for actionable conversations
Why does this matter for Value Based Care?
- This data set contained 378 scopes,
with anesthesia costs of $250,000
- Average anesthesia cost per scope
is $662, mostly with MDs
- Average CRNA cost per scope is
$323
- This analysis can help practices
choose efficient provider partners, helping the practice win in Value Based Care models
378 x $662 =
$250,236
378 patients x $323 =
$122,094 $128,142
in potential episode savings
*Guroo ACO has $10,000 to manage this patient’s total cost of care An aligned specialist is beating the Houston benchmark ($2,743*) by $1,000
Colonoscopy Episode
▪ A recent study from the Deloitte Center for Health Solutions found that access to cost information may drive more behavior change toward value-based care among physicians. ▪ The study also found that two-thirds of physicians have access to their own productivity and quality performance data, but cost information is less common.
Cost Data and Physician Performance
Source: Deloitte 2018 Survey of US Physicians
Which of the following types of performance information would compel you to reconsider how you practice? For each of the types of information you receive, can you recall an instance when the information made you reconsider or change how you practice?
Not Implemented Implemented My own performance on quality measures 65% 71% My own productivity measures 51% 57% Estimated patient out-of-pocket costs for different treatment options 39% 62% Cost or resource use for attributed patients 36% 53% Performance on quality measures for physicians/ facilities to which I refer 32% 59% Cost or resource use of physicians/ facilities to which I refer 23% 60% None of the above 26% N/A
How to Prepare
Specialists ✓ Get on the treadmill ✓ Work with payers and provider partners to obtain your data ✓ Participate in existing opportunities PCPs/ACOs ✓ Identify specialty partners who have aligned incentives ✓ Share data and clinical strategies with specialists Payers ✓ New world- price transparency ✓ Create opportunities for lowering cost and improving quality Hospitals ✓ Leverage data advantage to change clinical workflow models ✓ Use this adoption time to determine new revenue models
Thank You
Erica Maltby VP, Operations erica.maltby@texmed.org Dave Spalding CEO Dave.spalding@texmed.org